FDA Office of Training and Communication
Regulatory Counsel John Friel named deputy director of the CDER office Dec. 10. Friel formerly addressed small business issues in the Office of the Commissioner and moved into OTCOM when the Commissioner's office was restructured in June (1"The Pink Sheet" June 28, p. 23). Friel replaces Linda Brophy, who departed OTCOM to serve as a special assistant to Office of Postmarketing Drug Risk Assessment Deputy Director Peter Honig, MD
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth